Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brivanib versus placebo after sorafenib failure or intolerance in advanced hepatocellular carcinoma
RBR-28gdtzPhase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing Brivanib plus best supportive care with Placebo plus best supportive care (2 arms). Started Feb 2010; status: completed.
02
Drugs
brivanib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on RBR-28gdtz.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-28gdtz.